Evidence map›Paper›PMID 34895041›Full record

ArticleBioengineered2021

Maprotiline ameliorates isoflurane-induced microglial activation via regulating triggering receptor expressed in myeloid cells 2 (TREM2).

Rui Hu, Yongguan He, Zhigang Chen

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rui HuDepartment of Anesthesiology, Affiliated Hospital of Guilin Medical College, Guilin, China.
Yongguan HeDepartment of Anesthesiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefectrue, Enshi Tujia and Miao Autonomous Prefecture, Hubei, China.
Zhigang ChenDepartment of Anesthesia and Pain, wuhanxinzhou District People's Hospital, Wuhan, China.
Affiliated Hospital of Guilin Medical College · CNThe Central Hospital of Enshi Tujia and Miao Autonomous Prefecture · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoflurane-induced neurotoxicity has attracted much interest. Recent studies suggest that isoflurane causes microglial activation, resulting in an inflammatory response and microglial insult. Maprotiline is a novel drug that has been licensed as an antidepressant with considerable anti-inflammatory activity. However, it is still unknown whether maprotiline possesses a protective effect against isoflurane-induced microglial insult. Here, we found that maprotiline ameliorated isoflurane-caused reduction in BV2 microglial cell viability and lactate dehydrogenase (LDH) release. Maprotiline mitigated isoflurane-induced oxidative stress by inhibiting reactive oxygen species (ROS) production and increasing superoxide dismutase (SOD) activity. Isoflurane-induced expression and production of inflammatory markers including tumor necrosis factor (TNF-α), interleukin (IL)-1β, cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE

Indexed as

AnimalsBiomarkersCells, CulturedCell SurvivalCyclooxygenase 2DinoprostoneInflammationIsofluraneL-Lactate DehydrogenaseMaprotilineMembrane GlycoproteinsMiceMicrogliaMyeloid CellsOxidative StressReactive Oxygen SpeciesBiomarkersCyclooxygenase 2DinoprostoneIsofluraneL-Lactate DehydrogenaseMaprotilineMembrane GlycoproteinsReactive Oxygen SpeciesReceptors, ImmunologicSuperoxide DismutaseTrem2 protein, mouseinflammationIsofluranemaprotilinemicroglial activationoxidative stressTREM2

Identifiers

PMID34895041
PMCPMC8810129
OpenAlexW4200395293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.